Recently, the China Listed Companies Association announced the results of the "2025 Excellent Practice Cases of Internal Control for Listed Companies" selection. Eyebright Medical has been honored with the title of "2025 Excellent Practice Case of Internal Control for Listed Companies" in recognition of its exemplary compliance management and robust internal control system.

This selection process was guided by the Accounting Division of the Ministry of Finance and the Accounting Division of the China Securities Regulatory Commission (CSRC). It evaluated listed companies based on three key dimensions: the accuracy in identifying the characteristics and risks of economic activities, the innovation of internal control mechanisms, and the effectiveness of internal control implementation. The objective is to establish a "Chinese paradigm" for internal control practices.

Receiving this recognition affirms the regulatory authorities' acknowledgment of Eyebright Medical's ongoing commitment to developing a scientific and efficient internal control system. Moving forward, the company will steadfastly adhere to the principles of compliance and scientific rigor, further advancing the integration of internal control management with business innovation, and continuously fostering the internal momentum for high-quality development.